ArticleAmerican journal of medicine open2026
Cancer Survival at a Comprehensive Cancer Center Compared With Surveillance, Epidemiology, and End Results (SEER) Estimates.
Article in American journal of medicine open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Objective: We compared outcomes across common cancer types at an NCI-designated Comprehensive Cancer Center (NCI-CCC) (City of Hope) vs the U.S. Surveillance, Epidemiology, and End Results (SEER) national database. Cancer Centers offer a comprehensive approach to prevention, diagnosis, and treatment through tertiary services and by providing coordinated, personalized care. Methods: Propensity score matching (PSM) methods were employed in a 1:5 ratio for patients with incident cancers from 2004 to 2020 treated at COH vs reported in SEER. Results: The COH cohort had significantly superior overall survival (OS) compared with the SEER cohort across all examined cancer types after multivariable adjustment for key baseline characteristics and in the PSM analyses. For the PSM analyses: non-small cell lung cancer (NSCLC) hazard ratio (HR) 0.73, breast cancer HR 0.83, prostate cancer HR 0.62, colorectal cancer HR 0.74, pancreatic cancer HR 0.75, acute myeloid leukemia HR 0.79, acute lymphoid leukemia HR 0.77, and multiple myeloma HR 0.70 (all Conclusion: We found that cancer survival benefits were associated with patient care at an individual NCI-CCC employing state-of-the-art therapies and modern care. This work also highlights an opportunity to make adjusted survival outcomes more accessible to patients, complementing other types of comparative data now available. Further research could help to identify the drivers of observed survival advantages and promote the development of better guidelines and care models to improve outcomes for all patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.